 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- CTA101 / Nanjing Bioheng Biotech
CAR?T Cell Therapy With CRISPR/CAS9 Engineering for Relapsed/Refractory B?Cell Acute Lymphoblastic Leukemia, With Universal Dual Target CD19/CD22 () - Aug 31, 2023 - Abstract #SOHO2023SOHO_814;
No genotoxicity or chromosomal translocation associated with gene editing was observed. Six patients received infusions of CTA101 at doses of 1 (3 patients) and 3 (3 patients)
- | CTA101 / Nanjing Bioheng Biotech
Journal, CAR T-Cell Therapy: CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. (Pubmed Central) - Mar 17, 2022
CRISPR/Cas9-engineered universal CD19/CD22 CAR-T cells exhibited a manageable safety profile and prominent anti-leukemia activity. Universal dual-targeted CAR-T cell therapy may offer an alternative therapy for patients with r/r ALL.
- ||| CTA101 / Nanjing Bioheng Biotech
China's Nanjing Bioheng Biotech develolping CTA101, a Crispr-edited CD19/CD22 Car; 5/6 CR in r/r ALL, via He Huang #ASH20 $CRSP (Twitter) - Dec 6, 2020
- | CTA101 / Nanjing Bioheng Biotech
interesting that CTA-101 abstract (Twitter) - Dec 2, 2020
- Campath (alemtuzumab) / Sanofi, Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (Channel 21 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3226;
P1
Prior to CTA101 infusion, pts received pre-conditioning chemotherapy regimen consisting of cyclophosphamide, fludarabine and alemtuzumab...All pts experienced CRS (3 G1, 2 G2, 1 G3), and the G3 CRS recovered within 7 days with one dose of tocilizumab and glucocorticoids...Early data of cellular PK and efficacy illustrate that CRISPR gene editing does not curtail the expansion and anti-leukemia capacity of CAR-T. Updated data, including long term gene editing-related AEs, will be presented after further follow-up.
- | CTA101 / Nanjing Bioheng Biotech
New P1 trial, CAR T-Cell Therapy: A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy (clinicaltrials.gov) - Jan 12, 2020
P1, N=72, Recruiting, Sponsor: He Huang
- | CTA101 / Nanjing Bioheng Biotech
New P1 trial, CAR T-Cell Therapy: CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 5, 2019
P1, N=15, Recruiting, Sponsor: Kai Lin Xu; Jun Nian Zheng
- | CTA101 / Nanjing Bioheng Biotech
Trial initiation date, CAR T-Cell Therapy: CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Nov 1, 2019
P1, N=9, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
Updated data, including long term gene editing-related AEs, will be presented after further follow-up. Initiation date: Aug 2019 --> Dec 2019
- | CTA101 / Nanjing Bioheng Biotech
New P1 trial, CAR T-Cell Therapy: CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jul 18, 2019
P1, N=9, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University